Just arsenic Novo Nordisk showed signs of a recovery, different acold ablution deed investors arsenic the drugmaker astonishment pre-released its 2026 forecast precocious Tuesday, sending shares tumbling.
Novo Nordisk's banal plummeted 18% successful Copenhagen aboriginal Wednesday, tracking losses seen successful its American depositary shares connected Tuesday and much than wiping retired gains seen truthful acold this year.
"People should expect that it goes down earlier it comes backmost up," CEO Mike Doustdar told CNBC's "Early Edition Europe" connected Wednesday, highlighting the headwinds of importantly little U.S. pricing connected its best-selling value nonaccomplishment cause Wegovy.
"We did not spell into the details of the magnitude of that – with the guidance we are giving that range."
It follows Novo's guidance for 2026 income and operating nett some declining betwixt 5% and 13%, acold worse than analysts had expected.
Barclays analysts said immoderate mightiness suggest the usher to beryllium a "kitchen sink" that volition beryllium beaten, "though we enactment the aforesaid was said past year, and this proved not to beryllium the case."
In July past year, Novo slashed guidance for 2025, citing a challenging U.S. market, starring to shares to clang 23% connected the day.
A U-shaped recovery?
"We are creating affordability for the patients, millions of patients that are close present successful request of GLP-1 products, but simply could not spend it. To bash that abbreviated term, you person to instrumentality a headwind. But of course, there's a precise agelong tailwind for years to come," Doustdar told CNBC.
The institution has flagged challenges astir pricing successful its biggest market, the U.S., owed to some contention from compounding pharmacies that merchantability cheaper knockoff versions of semaglutide – the progressive constituent successful Wegovy and Ozempic – arsenic good arsenic from main rival U.S.-based Eli Lilly.
But optimism grew aboriginal this twelvemonth arsenic the motorboat of the Wegovy pill successful the U.S. went amended than adjacent Novo had expected. "We knew it's going to beryllium the champion successful presumption of efficacy of 16.6% we had expected it to bash well, but we did not deliberation that aft 4 weeks of introduction, we volition person 170,000 radical connected the pill," said Doustdar.
"No substance however good it does successful the archetypal period, the terms deed connected the existing concern trumps, basically, the large pill motorboat that we've had."
While Novo has worked to negociate expectations going into its full-year results, wherever it besides announced guidance for the twelvemonth to come, the marketplace did not spot this coming.
"The question becomes if the betterment from here, [will be] a Nike swoosh oregon U-shaped recovery," noted HSBC's Rajesh Kumar.
English (US) ·